Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Pha...(nt of the CMV vaccine; whether the CMV v...),Health

Date:11/12/2008

nt of the CMV vaccine; whether the CMV vaccine will achieve the safety and efficacy endpoints in the Phase 2 trial; whether T-cell responses will control CMV reactivation and disease; whether the interim evaluation of immunogenicity in the Phase 2 trial will be predictive of clinical benefit, and if so, whether such benefit will be confirmed with clinical efficacy results in the second quarter of 2009, if at all; whether the company will expand development of a CMV vaccine to address prevention of congenital disease, and if so, whether such results will be successful; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

(1) Avetisyan G, et al. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant. 2006 Nov;38(10):687-92.

Avetisyan G, et al. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant. 2007 Nov;40(9):865-9.

Contact: Alan R. Engbring

(858) 646-1127

Website: http://www.vical.com

'/>"/>

SOURCE Vical Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
2. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
3. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
4. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
6. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
7. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
8. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
9. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
10. Promise of Vicals CMV Vaccine Noted by Independent Experts
11. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap